bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.383059; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Title: Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model Authors: Felicia Reinitz1†, Elizabeth Chen1†, Benedetta Nicolis di Robilant1†, Bayarsaikhan Chuluun2, Jane Antony1, Robert C. Jones3, Neha Gubbi1, Sai Saroja Kolluru3, Dalong Qian1, Katja Piltti4, Aileen Anderson4, Michelle Monje1, H. Craig Heller2, Stephen Quake3, Michael F. Clarke1* Affiliations: 1Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California 94305, USA. 2Department of Biology, Stanford University School of Medicine, Stanford, California 94305, USA. 3Bioengineering, Stanford University School of Engineering and Medicine, Stanford, California, 94305, USA. 4Sue and Bill Gross Stem Cell Research Center, University of California, Irvine *Lead contact and all other correspondence to:
[email protected] †These authors contributed equally. 1 Summary: Alzheimer’s disease (AD) is a progressive neurodegenerative disease observed with 2 aging that represents the most common form of dementia. To date, therapies targeting end-stage 3 disease plaques, tangles, or inflammation have limited efficacy. Therefore, we set out to identify 4 an earlier targetable phenotype. Utilizing a mouse model of AD and human fetal cells harboring 5 mutant amyloid precursor protein, we show cell intrinsic neural precursor cell (NPC) dysfunction 6 precedes widespread inflammation and amyloid plaque pathology, making it the earliest defect in 7 the evolution of disease.